Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 7687 results

  1. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery

    Diagnostics guidance
    Published
    7 August 2013
    View recommendations

    Sections for DG8

  2. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic

    Diagnostics guidance
    Published
    14 August 2013
    View recommendations

    Sections for DG9

  3. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

    Diagnostics guidance
    Published
    20 August 2014
    View recommendations

    Sections for DG13

  4. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

    Diagnostics guidance
    Published
    10 December 2014
    View recommendations

    Sections for DG16

  5. Devices for remote monitoring of Parkinson's disease (DG51)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease

    Diagnostics guidance
    Last updated
    25 January 2024
    View recommendations

    Sections for DG51

  6. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  7. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346

    In development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease

    Diagnostics guidance
    Published
    17 February 2016
    View recommendations

    Sections for DG22

  9. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

    Medical technologies guidance
    Last updated
    1 October 2018
    View recommendations

    Sections for MTG16

  10. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

    Medical technologies guidance
    Published
    12 November 2014
    View recommendations

    Sections for MTG21

  11. Alpha-Stim AID for anxiety disorders (MTG56)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

    Medical technologies guidance
    Published
    8 March 2021
    View recommendations

    Sections for MTG56

  12. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

    Medical technologies guidance
    Published
    27 January 2022
    View recommendations

    Sections for MTG65

  13. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  14. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  15. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016